Orvical: Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting Conditions

• Sponsor: World Medicine ILAC SAN. ve TIC. A.S. (Industry)
• Overall Status: Completed
• CT.gov ID: NCT04386876
• Collaborator: Novagenix Bioanalytical Drug R&D Center (Other), Farmagen Ar-Ge Biyot. Ltd. Sti (Other)
• Enrollment: 30
• Locations: 2
• Arms: 2
• Actual Duration (Months): 1.4
• Patients Per Site: 15
• Patients Per Site Per Month: 10.9

Study Details

Study Description

Brief Summary

A single dose of Reference product containing 200 mg lopinavir and 50 mg ritonavir fixed dose combination and a single dose of Test product containing 200 mg lopinavir and 50 mg ritonavir fixed dose combination or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions.

Condition or Disease	Intervention/Treatment	Phase
Bioequivalence	Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet; Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet	Phase 1

Detailed Description

The subjects will me isolated at the dorm during 5 days before the dosing.

Study Design

• Study Type: Interventional
• Actual Enrollment: 30 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Intervention Model Description: Single Oral Dose,Two Treatment,Four-period,Full-replicated,Cross-overSingle Oral Dose,Two Treatment,Four-period,Full-replicated,Cross-over
• Masking: None (Open Label)
• Primary Purpose: Other
• Official Title: Randomized, Single Oral Dose,Two Treatment,Four-period,Full-replicated,Cross-over Trial to Assess the BE of Orvical 200 mg/50 mg FT in Comparison With Kaletra 200 mg/50 mg FT in Healthy Male Subjects Under Fasting Conditions
• Actual Study Start Date: Apr 30, 2020
• Actual Primary Completion Date: May 22, 2020
• Actual Study Completion Date: Jun 11, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Orvical-Kaletra-Orvical-Kaletra In first and third periods of the study, participants received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. In second and fourth periods, they received Kaletra 200 mg/50 mg Film CoatedTablet manufactured by AbbVie Deutschland GmbH & Co.-Germany. All periods were performed under fasting state.	Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet; Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).; Other Names: Orvical 200 mg/50 mg Film Tablet ; Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet; Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH & Co.-Germany); Other Names: Kaletra 200 mg/50 mg Film Coated Tablet
Experimental: Kaletra-Orvical-Kaletra-Orvical In first and third periods of the study, participants received Kaletra 200 mg/50 mg Film Coated Tablet manufactured by AbbVie Deutschland GmbH & Co.-Germany. In second and fourth periods, they received Orvical 200 mg/50 mg Film Tablet manufactured by World Medicine-Turkey. All periods were performed under fasting state.	Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Tablet; Lopinavir/Ritonavir film tablet containing 200 mg lopinavir and 50 mg ritonavir (World Medicine-Turkey).; Other Names: Orvical 200 mg/50 mg Film Tablet ; Drug: Lopinavir/Ritonavir 200 mg/50 mg Film Coated Tablet; Lopinavir/Ritonavir film coated tablet containing 200 mg lopinavir and 50 mg ritonavir(AbbVie Deutschland GmbH & Co.-Germany); Other Names: Kaletra 200 mg/50 mg Film Coated Tablet

Outcome Measures

Primary Outcome Measures

1. Primary PK End Points [12 weeks]

   AUC0-tlast of lopinavir and ritonavir

2. Primary PK End Points [13 weeks]

   Cmax of lopinavir and ritonavir

Eligibility Criteria

Criteria

• Ages Eligible for Study: 20 Years to 40 Years
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

1. Healthy Caucasian male subjects aged between 20 and 40 years,

2. Non smokers or smoking maximum 5 cigarettes a day, those who won't smoke or drink coffee during the study period,

3. Negative Covid-19 Rapid Test results and two Negative Covid-19 PCR test results,

4. Negative alcohol breath test results,

5. Normal physical examination at screening visit,

6. Having the Body Mass Index ranged between 18.5-30 kg/m2 (see Appendix I) which is in the desirable range according to the age,

7. Ability to communicate adequately with the investigator himself or his representatives,

8. Ability and agreement to comply with the study requirements,

9. Normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 90 bpm,

10. Normal/ acceptable 12-lead electrocardiographic results at least after 5 minutes of rest,

11. Laboratory results within normal range or clinically non-significant (CBC, glucose, urea, uric acid, creatinine, estimated GFR (eGFR), total bilirubin, sodium, potassium, calcium, chloride, SGOT (AST), SGPT (ALT), GGT, alkaline phosphatase, total protein and urinalysis), drug addiction scanning in urine results in negative (amphetamine, barbiturate, benzodiazepine, cannabinoid, cocaine, opiate),

12. Understanding of the study and agreement to give a written informed consent according to section 20.3.

13. Volunteer's compliance with isolation rules defined at study protocol

Exclusion Criteria:

1. Who have atopic constitution or asthma or known allergy for lopinavir and ritonavir or any other ingredients of the products.

2. Any history or presence of clinical relevance of cardiovascular (myocardial infarction/ ischaemia and/or QT prolongation etc.), neurological, musculoskeletal, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphyria.

3. Baseline ECG should be performed at screening. Exclude subjects having a QTc > 440 ms

4. Symptomatic or asymptomatic orthostatic hypotension at screening or before the first drug administration defined by a decrease of SBP more than 20 mmHg or DBD more than 10 mmHg occurs between sitting/supine to standing position subject will be excluded (if it deemed necessary by the investigator),

5. Presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy.

6. Subjects who have given more than 400 mL blood within the last two months before the first drug administration and subjects who have participated to any drug research within the last two months before the first drug administration.

7. Subjects suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgement.

8. Subjects who used any of prescribed systemic or topical medication (including OTC medication) within 2 weeks (or six elimination half lives of this medication, whichever is longer) before the initiation of the study (except single doses of analgesics which have no drug interaction with study product).

9. Use of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.

10. Subjects who have any chronic disease which might interfere with absorption, distribution, metabolism or excretion of the drug.

11. Subjects who regular consumed of beverages or food containing methylxanthines (e.g. coffee, tea, cola, caffeine, chocolate, sodas,) equivalent to more than 500 mg methylxanthines per day.

12. Subjects who has taken any grapefruit or grapefruit juice during 7 days prior to drug administration, during the study.

13. History of allergic response to heparin.

14. History of drug abuse.

15. History of alcohol abuse and/or regular use of more than 2 units of alcohol per day or 10 units per week and/or positive alcohol breath test results (Note: one unit of alcohol equals 250 mL beer, 125 mL wine or 25 mL spirits).

16. Positive blood test for HBV, HCV and HIV.

17. Who have relationship to the investigator.

18. Who are not suitable to any of inclusion criteria.

19. History of difficulty of swallowing.

20. Intake of depot injectable solutions (including study medications) within 6 months before start of the study.

21. Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before start of the study.

22. Special diet due to any reason, e.g. vegetarian.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Novagenix Drug R&D Center	Akyurt	Ankara	Turkey	06970
2	Farmagen Ar-Ge Biyot. Ltd. Sti.	Sahinbey	Gaziantep	Turkey	27000

Sponsors and Collaborators

• World Medicine ILAC SAN. ve TIC. A.S.
• Novagenix Bioanalytical Drug R&D Center
• Farmagen Ar-Ge Biyot. Ltd. Sti

Investigators

• Principal Investigator: Muradiye Nacak, MD,PhD, Farmagen Ar-Ge Biyot. Ltd. Sti

Study Documents (Full-Text)

• Informed Consent Form - Apr 17, 2020
• Study Protocol and Statistical Analysis Plan - Apr 17, 2020

More Information

Publications

None provided.

• Responsible Party: World Medicine ILAC SAN. ve TIC. A.S.
• ClinicalTrials.gov Identifier: NCT04386876
• Other Study ID Numbers: NOV2020/01911; FARGE365
• First Posted: May 13, 2020
• Last Update Posted: Dec 31, 2020
• Last Verified: Nov 1, 2020

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by World Medicine ILAC SAN. ve TIC. A.S.: COVID-19 drug treatment; Ritonavir; Lopinavir; Antiviral Agents; Kaletra; Novagenix; Farmagen
• Additional relevant MeSH terms: Ritonavir; Lopinavir

Study Results

No Results Posted as of Dec 31, 2020